”TIGR® Matrix can become an important part of our surgical procedure, mainly to prevent early complications which could prevent effective downstream chemotherapy,“ says Haile Mahteme, assistant professor and founder of Uppsala Cancer Clinic. “If we can prevent these complications we can certainly improve the quality of life of our patients even more.”
TIGR® Matrix is an innovative product from Swedish owned Novus Scientific that has been marketed initially in the United States since 2010 and in Europe since 2011. The technology is based on absorbable synthetic polymers in the form of a surgical mesh, designed to reinforce weakened soft tissue during a healing and regeneration period. TIGR® Matrixhas been used extensively in general and plastic surgery including such applications as abdominal wall reconstruction and breast reconstruction following cancer surgery.
”We are excited to see Uppsala Cancer Clinic adopting TIGR® Matrix for this application,” says Henrik Hjort, co-inventor and Product Manager at Novus Scientific in Uppsala. “There is a tremendous potential for using TIGR® Matrix as a prophylactic reinforcement when closing abdominal walls. This can become standard practice for many different procedures in order to prevent incisional hernias from occurring later. Prevention of subsequent afflictions related to the initial surgery will be a key element to good health economics in future and we are glad to work together with an Uppsala clinic to achieve it.”
Before the arrival of TIGR® Matrix, most surgical meshes implanted to reinforce soft tissue defects were made from permanent plastic materials or cadaver derived biologic materials, commonly taken from either human, bovine or porcine sources. Permanent devices have been associated with risks such as chronic pain, which is when nerves can get trapped in the mesh. Now, with a long-term absorbable alternative such as TIGR® Matrix, the risk for eventual chronic complications is reduced and makes the prophylactic reinforcement of weakened tissues in order to prevent defects from occurring a reality.
About Uppsala Cancer Clinic
Uppsala Cancer Clinic (UCC) is a highly specialised clinic with a staff of around 30 professionals all of whom are co-owners. UCC is situated at Uppsala’s Samariterhemmet’s Sjukhus and boasts Scandinavia’s highest competence in peritoneal cancer treatment. Every doctor and a surgical nurse has publicly defended their research work and the majority of staff have well over a decade of experience in the successful treatment of patients with peritoneal cancer and active healthcare experience ranging from 5 to 30 years.
Contact Uppsala Cancer Clinic:
Susanne Svahn,CEO, email@example.com, +46 76-1636770
Contact Novus Scientific:
Henrik Hjort, firstname.lastname@example.org, +46 70-6009770
For more information: www.tigrmatrix.com
About Novus Scientific
Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable (100% absorbable) synthetic medical devices. Global HQ is in Singapore while European Headquarters and the core R&D function are in Uppsala, Sweden. The company’s roots are Swedish as all the founders of Novus Scientific are previous owners / senior managers / members of the soft tissue-engineering project within Uppsala-based, Radi Medical Systems AB (now owned by St. Jude Medical Inc). The US Division, Novus Scientific, Inc. is headquartered in San Diego.
TIGR® Matrix - The world’s 1st long-term resorbable, 100% absorbable synthetic mesh with unique patented dual-fiber construction, designed for gradually increasing mechanical compliance.
TIGR® is a registered trademark of Novus Scientific Pte. Ltd